Pexiganan CAS NO.147664-63-9

pexiganan is a 22-amino acid linear peptide developed by GlaxoSmithKline and Genaera (formerly MagaininPharmaceuticals). It acts as a broad-spectrum topical antimicrobial agent for the treatment of infection in diabetic foot ulcers. Peixiganam, originally isolated from the abdominal skin of Xenopus, is an animal-derived peptide antibacterial drug. It is a member of the peptide antibiotic family magainin and the second new antibiotic family in the past 20 years. It is effective against more than 3,000 isolated strains. These include bacteria (Gram-negative, Gram-positive, and anaerobic), amoebae, fungi, and parasites. Mechanism of action Peixiganan works differently from other antibiotics in that it kills bacteria by attacking their cell membranes, whereas most other antibiotics disable key bacterial proteins. Therefore, it is expected to become a new generation of antibacterial agents. The invention provides a method for the synthesis of pexiganam. The steps are as follows: Step 1, the dipeptide fragment Fmoc-Lys(Boc)-Lys(Boc)-OH is synthesized by liquid phase method; Step 2: The amino acids with N-terminal Fmoc protection and side chain protection were sequentially coupled according to the main chain peptide sequence of peisicanan by using the solid phase synthesis method, and the amino acids at positions 7 and 8, 10 and 11, 21 and 22 were coupled by the dipeptide fragments Fmoc-Lys(Boc)-Lys(Boc)-OH. Step 3: Peptide resin was cleaved, purified, and lyophilized to obtain pesiganan. Among them, the synthesis method of the dipeptide fragment Fmoc-Lys(Boc)-Lys(Boc)-OH described in step 1 includes the following steps: 1)Fmoc-Lys(Boc)-OH, HOSu and DCC were coupled to obtain Fmoc-Lys(Boc)-OSu, and then Fmoc-Lys(Boc)-OSu reacted with H-Lys(Boc)-OH to obtain the diskin fragment Fmoc-Lys(Boc)-Lys(Boc)-OH.

pexiganan is a 22-amino acid linear peptide developed by GlaxoSmithKline and Genaera (formerly MagaininPharmaceuticals). It acts as a broad-spectrum topical antimicrobial agent for the treatment of infection in diabetic foot ulcers. Peixiganam, originally isolated from the abdominal skin of Xenopus, is an animal-derived peptide antibacterial drug. It is a member of the peptide antibiotic family magainin and the second new antibiotic family in the past 20 years. It is effective against more than 3,000 isolated strains. These include bacteria (Gram-negative, Gram-positive, and anaerobic), amoebae, fungi, and parasites. Mechanism of action Peixiganan works differently from other antibiotics in that it kills bacteria by attacking their cell membranes, whereas most other antibiotics disable key bacterial proteins. Therefore, it is expected to become a new generation of antibacterial agents. The invention provides a method for the synthesis of pexiganam. The steps are as follows: Step 1, the dipeptide fragment Fmoc-Lys(Boc)-Lys(Boc)-OH is synthesized by liquid phase method; Step 2: The amino acids with N-terminal Fmoc protection and side chain protection were sequentially coupled according to the main chain peptide sequence of peisicanan by using the solid phase synthesis method, and the amino acids at positions 7 and 8, 10 and 11, 21 and 22 were coupled by the dipeptide fragments Fmoc-Lys(Boc)-Lys(Boc)-OH. Step 3: Peptide resin was cleaved, purified, and lyophilized to obtain pesiganan. Among them, the synthesis method of the dipeptide fragment Fmoc-Lys(Boc)-Lys(Boc)-OH described in step 1 includes the following steps: 1)Fmoc-Lys(Boc)-OH, HOSu and DCC were coupled to obtain Fmoc-Lys(Boc)-OSu, and then Fmoc-Lys(Boc)-OSu reacted with H-Lys(Boc)-OH to obtain the diskin fragment Fmoc-Lys(Boc)-Lys(Boc)-OH.